Related Experiment Video
Updated: May 5, 2026
15:18
Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
Published on: July 30, 2009
17.2K
Challenges in conducting pediatric drug trials
1Department of Pediatrics, The Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
The Journal of Allergy and Clinical Immunology
|September 13, 2000
Summary
Pediatric asthma treatment is shifting towards anti-inflammatory drugs to prevent chronic symptoms. However, significant knowledge gaps and research challenges persist in pediatric drug development.
Area of Science:
- Pediatric Pharmacology
- Respiratory Medicine
- Clinical Therapeutics
Background:
- Historically, pediatric drug use focused on symptom relief, excluding infection treatments.
- Asthma management is evolving towards anti-inflammatory agents to address the root causes of bronchoconstriction.
- Research in adults highlights the potential of early intervention to prevent chronic adult disease.
Purpose of the Study:
- To review the shift in pediatric asthma treatment towards anti-inflammatory therapies.
- To highlight the ongoing challenges in pediatric drug research and development.
- To underscore the importance of effective pediatric drug trials for long-term health outcomes.
Main Methods:
- Literature review of pediatric asthma treatment evolution.
- Analysis of the impact of anti-inflammatory agents in pediatric populations.
- Discussion of regulatory and research hurdles in pediatric drug trials.
Main Results:
- Asthma treatment has transitioned from symptom management to addressing underlying inflammation.
- Effective childhood therapy may prevent the development of chronic adult asthma.
- A significant knowledge gap persists regarding drug efficacy and safety in children.
Conclusions:
- The paradigm for pediatric asthma care is shifting towards preventative anti-inflammatory strategies.
- Addressing research and regulatory challenges is crucial for advancing pediatric pharmacology.
- Further investigation and trials are essential to optimize drug therapy for children and prevent adult chronic conditions.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:29Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
558
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
558
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
413
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
413